- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03918317
A Study of the Use of AirXpanders AeroForm in Patients Undergoing Post-Mastectomy Radiation Therapy
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Primary objective:
To assess the proportion of successful initial phase of tissue expander/implant based breast reconstructions (no reconstruction failure or unexpected return to the operating room) following post-mastectomy radiation therapy in participants with AeroFormplaced.
Secondary objectives:
- To evaluate the rate of successful exchange of tissue expander for implant
- To evaluate the rate of reconstruction revisions
- To evaluate CTCAE acute and chronic toxicity rates, infections and cosmetic outcomes
- To evaluate dosimetry to treatment targets as well as organs at risk (heart, lungs) with AeroFormas compared to traditional reconstruction techniques.
- To evaluate time to initiation of chemotherapy and/or radiotherapy.
- To evaluate clinical outcomes-local recurrence, regional recurrence, distant metastases, survival
- To evaluate participant breast reconstruction related QOL with the AirXpander AeroFormdevice
This is a phase II trial evaluating the use of the intervention in participants with breast cancer undergoing post-mastectomy radiation therapy in order to define the toxicity profile and associated subsequent successful surgical reconstruction rate
Type d'étude
Phase
- N'est pas applicable
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Subjects must have histologically of invasive breast cancer.
- Subjects must be planned for unilateral mastectomy
- Subjects must be planned for reconstruction. Pre-pectoral or sub-pectoral reconstruction allowed. Final reconstruction must be implant
- ECOG Performance status <2
- Subject must have features that will necessitate post-mastectomy radiation therapy:
- Tumors > 5 cm
- Axillary node positive disease (pathologic confirmation)
- Clinical features prior to neoadjuvant chemotherapy to require post-mastectomy radiation therapy
- Recurrent disease without previous radiation
- Clinically node negative participants with positive SLN at surgery
- Internal mammary nodal involvement (clinical assessment)
- Subjects must have no clinical or radiographic evidence of distant metastases (imaging not required unless indicated as part of standard of care)
- Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving CT simulation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- Subjects must have the ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Subjects with metastatic disease
- Subjects receiving any other investigational agents.
- Subjects treated with non-standard radiotherapy (hypofractionation, hyperfractionation, partial breast/axilla)
- Subjects with active infection requiring IV antibiotics
- Subject has a history or current evidence of any condition, therapy, or laboratoryabnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Subject has received prior radiation therapy to neck, breast, or chest or other area that will result in overlap.
- Pregnant or breastfeeding women or expecting to conceive children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last day of trial treatment are excluded from this study because of the potential toxicities of radiation therapy. Additionally, because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with AirXpanders, breastfeeding women will be excluded. These potential risks may also apply to other agents used in this study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: AirXpanders AeroFormtissue expander + Radiation therapy
AirXpanders AeroFormtissue expander in participants with breast cancer undergoing post-mastectomy radiation therapy in order to define the toxicity profile and associated subsequent successful surgical reconstruction rate.
|
The AeroFormdevice will be placed in an immediate fashion at the time of mastectomy in a submuscular, prepectoral or dual-plane approach.
The tissue expander will be minimally inflated intraoperatively to minimize dead space and while facilitating tension free closure.
Participants will undergo standard postoperative management, and will be given instructions on utilization of the device, including daily expansion until desired volume is reached as determined b surgeon and participant agreement.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Rate of successful reconstructions following radiation therapy
Délai: up to 6 months following permanent implant placement
|
up to 6 months following permanent implant placement
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Rate of implant success at 6months following replacement.
Délai: up to 6 months following permanent implant placement
|
up to 6 months following permanent implant placement
|
|
Rate of reconstruction revisions from Aeroform placement throughout study.
Délai: up to 6 months following permanent implant placement
|
up to 6 months following permanent implant placement
|
|
Time to implant exchange from Aeroform placement.
Délai: up to 6 months following permanent implant placement
|
up to 6 months following permanent implant placement
|
|
Time to initiation of adjuvant chemotherapy following initial surgery (when applicable).
Délai: up to 6 months following permanent implant placement
|
up to 6 months following permanent implant placement
|
|
Time to initiation of radiation therapy following initial surgery
Délai: up to 6 months following permanent implant placement
|
up to 6 months following permanent implant placement
|
|
Cosmetic outcomes per the aesthetics scale
Délai: up to 6 months following permanent implant placement
|
13-question assessment with scores ranging from 13 - 65, higher scores indicating better aesthetics
|
up to 6 months following permanent implant placement
|
Quality of life based on the BREAST-Q scales
Délai: up to 6 months following permanent implant placement
|
Full name BREAST-Q- Reconstruction Module version 2.0, higher is better outcome
|
up to 6 months following permanent implant placement
|
Quality of life based on the Breast satisfactions scales
Délai: up to 6 months following permanent implant placement
|
Full name BREAST-Q- Reconstruction Module version 2.0, higher is better outcome
|
up to 6 months following permanent implant placement
|
Number of participants who experience acute toxicity per CTCAE version 4.0
Délai: up to 6 months following permanent implant placement
|
See AE/SAE section
|
up to 6 months following permanent implant placement
|
Chronic toxicity per CTCAE, Baker scoring
Délai: up to 6 months following permanent implant placement
|
Full name CTCAE Toxicity/Baker Capsular Contracture, Higher- worse CTCAE and Baker
|
up to 6 months following permanent implant placement
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Chirag Shah, The Cleveland Clinic
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Anticipé)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- CASE2119
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Cancer du sein
-
AstraZenecaRecrutementAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerEspagne, États-Unis, Belgique, Royaume-Uni, France, Hongrie, Canada, Corée, République de, Australie